Summary
Mice were dosed with [3H]2′,3′-dideoxyadenosine ([3H]ddA) in three procedures: intravenously, intraperitoneally, and interperitoneally following a dose of 2′ -deoxycoformycin (dCF). For mice dosed intravenously, the content of radioactivity in plasma and tissue samples were essentially constant after 30 min. Of the radioactivity in plasma and brain samples collected between 30 min and 24 hr, more than 94% was present as 3H2O, indicating that most of the tritium from [3H]ddA had exchanged with water. No intact ddA was detected, and the deamination product, 2′,3′ -dideoxyinosine (ddI), was present only transiently. In the urine, the major radioactive material was [3H]ddI. Also detected were 3H2O and small amounts of [3H]hypoxanthine and [3H]ddA. Following intraperitoneal doses to mice, levels of radioactivity in plasma, liver, and kidney increased to a maximum by 15–30 min after dosing but dropped to essentially constant levels thereafter, again indicating that the tritium had exchanged with water. At 5, 15, and 30 min after dosing, ddI was the major radioactive component in plasma. Only small amounts of ddA were present. When dCF was administered 24 hr prior to intraperitoneal [3H]ddA, levels of radioactivity in plasma, liver, and kidney reached a maximum at 30 to 60 min after dosing and decreased to essentially constant levels thereafter. The dCF transiently inhibited the deamination of ddA to ddI, since, in plasma, [3H]ddA was the main radioactive component at 5 and 15 min after dosing. Comparison of HPLC assays based on radioactivity detection and UV absorbance showed that they were equivalent for measuring ddA and ddI in samples derived from dosed mice. Therefore, exchange of tritium must have occurred at a metabolic step beyond ddI.
For mice dosed intravenously and orally with unlabeled ddI, there was evidence of a saturated process. Nevertheless, for the high and low intravenous doses of ddI, the percent of dose excreted in the urine as unchanged drug was the same.
Similar content being viewed by others
References
Mitsuya H, Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Nat Acad Sci USA 83: 1911–1915, 1986
Baba M, Pauwels R, Herdewijn P, De Clerq E, Desmyter J, Vandeputte M: Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochim Biophys Res Comm 142:128–134, 1987
Mitsuya H, Jarrett RF, Matsukura M, Di Marzo Veronese F, DeVico AL, Sarngadharan MG, Johns DG, Reitz MS, Broder S: Long-term inhibition of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc Nat Acad Sci USA 84:2033–2037, 1987
Hao Z, Dalal M, Cooney DA, Balzarini J, Mitsuya H, Broder S, Johns DG: A comparison of 2′,3′-dideoxynucleoside-5′-triphosphates as inhibitors of retroviral reverse transcriptases. Proc Amer Assoc Cancer Res 28:323, 1987
Balzarini J, Kang G-J, Dalal M, Herdewijn P, De Clerq E, Broder S, Johns DG: The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′, 3′-didehydro-2′, 3′-dideoxyribonucleosides: A comparison with parental 2′, 3′ -dideoxyribonucleosides. Mol Pharmacol 32:162–167, 1987
Woo, PWK, Dion HW, Lange SM, Dahl LT, Durham LJ: A novel adenosine and ara-A deaminase inhibitor, (R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo [4,5-d] [1,3-diazepin-8-ol]. J Heterocyclic Chem 11:641–643, 1974
Placke ME, Page JG, Colling KA, Wientjes GM, Grieshaber CK, Tomaszewski JE: Single-dose pharmacokinetics and bioavailability study of 2′,3′-dideoxyadenosine in beagle dogs and rats. Toxicologist 8:89, 1988
Stolz M, El-Hawari M, Litle L, Alm P, Tomaszewski J, Grieshaber C. Pharmacokinetics and bioavailability of the anti-AIDS drug, 2′,3′ -dideoxyinosine (NSC-612049) in beagle dogs. Proc Am Assoc Cancer Res 29:505, 1988
Elvidge JA, Jones JR, O'Brien CA, Evans EA: Isotopic hydrogen exchange in purine, adenine, adenosine, and benzimidazole. Chem Commun 394–395, 1971
Plunkett W, Cohen SS: Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res 35:1547–1554, 1975
Cooney DA, Ahluwalia G, Mitsuya H, Fridland A, Johnson M, Hao Z, Dalal M, Balzarini J, Broder S, Johns DG: Initial studies on the cellular pharmacology of 2′, 3′-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 36:1765–1768, 1987
Stoeckler JD, Cambor C, Parks Jr RE: Human erythrocytic purine nucleoside phosphorylase: Reaction with sugarmodified nucleoside substrates. Biochemistry 19:102–107, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
El Dareer, S.M., Tillery, K.F., Kalin, J.R. et al. Disposition of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in mice. Invest New Drugs 7, 139–146 (1989). https://doi.org/10.1007/BF00170850
Issue Date:
DOI: https://doi.org/10.1007/BF00170850